Talk by Luke Timmerman will apply teamwork lessons learned from his 2018 Mount Everest climb, to conquering the “Everests” of cancer research
Servier Group and Servier Pharmaceuticals, the US subsidiary of the global French pharmaceutical company will be presenting data from multiple studies at presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago 31 May- 4 June 2019. This is the company's first ASCO since establishing their US presence in late 2018.
On Saturday, 1 June at 6 pm CT, Servier Pharmaceuticals is sponsoring “Navigating the ‘Mount Everests' of the Cancer Landscape,” an event featuring biotech journalist, author and mountaineer Luke Timmerman. At the event, Timmerman will apply leadership and teamwork lessons learned from his climb to the summit of Mount Everest in 2018 to conquering the “Everests” encountered every day in cancer research and development.
Sponsorship donations are dedicated to Climb to Fight Cancer, benefiting the Fred Hutchinson Cancer Research Center.
“Servier Pharmaceuticals is proud to exemplify our strengthened presence and dedication to growth in the US by debuting with such a robust presence at ASCO 2019,” said David K Lee, Servier Pharmaceuticals CEO. “In addition to the science, we are also thrilled to be working with Luke Timmerman, whose focus on innovations in oncology and passion for charitable giving align with our values as an organisation.”
Servier officially opened its American headquarters earlier this month with an immediate focus on oncology treatment and care. Oncology is a strategic priority for Servier, as demonstrated by the company's acquisition of Shire's oncology business in 2018 and by a growing number of research programmes within the field.
In the coming two years, oncology will account for 50% of the company's R&D budget, funding 700 employees over 50 countries. Currently, five treatments are available on the market and Servier group is developing 12 new therapeutic options.
Servier has forged 21 partnerships with academic institutions as well as with industrial partners and/or biotechnology companies. With this range of worldwide partners dedicated to innovation for the treatment of cancer, Servier's research in oncology is focused on therapies aimed at restoring programmed cell death (apoptosis) in cancer cells, and on mobilising the immune system against cancer cells (immuno-oncology).
“The depth and breadth of the Servier oncology pipeline is evidenced by our robust showing at ASCO 2019,” said Claude Bertrand, Executive VP of Research and Development at the Servier Group.
The following abstracts will be presented at this year's conference:
Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukaemia/lymphoma: Results of DFCI 11-001
RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer —Preliminary findings from part 1 dose-defining study. Paz-Ares et al. Poster presentation.
A multicenter phase Ib/II study of nalirinotecan, 5fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer. Sahai et al.